Edition:
United States

Synergy Pharmaceuticals Inc (SGYP.O)

SGYP.O on Nasdaq

3.90USD
11:56am EDT
Change (% chg)

$-0.02 (-0.51%)
Prev Close
$3.92
Open
$3.93
Day's High
$3.97
Day's Low
$3.86
Volume
1,234,646
Avg. Vol
6,333,411
52-wk High
$7.15
52-wk Low
$3.25

Latest Key Developments (Source: Significant Developments)

Synergy Pharmaceuticals reports Q1 sales $100,000
Wednesday, 10 May 2017 04:54pm EDT 

May 10 (Reuters) - Synergy Pharmaceuticals Inc :Synergy Pharmaceuticals reports first quarter 2017 financial results and business update.Q1 sales $100,000.Q1 revenue view $25,000 -- Thomson Reuters I/B/E/S.Qtrly net loss per common share, basic and diluted $0.30.Q1 earnings per share view $-0.23, revenue view $25000.00 -- Thomson Reuters I/B/E/S.  Full Article

Synergy Pharmaceuticals appoints Gary Gemignani as chief financial officer
Monday, 17 Apr 2017 08:00am EDT 

April 17 (Reuters) - Synergy Pharmaceuticals Inc -:Synergy Pharmaceuticals appoints Gary G. Gemignani as chief financial officer.Gemignani replaces senior vice president, finance, Bernard Denoyer.Bernard Denoyer, who will assist in transition process until his retirement on July 1, 2017.  Full Article

Synergy Pharmaceuticals announces issuance of three new patents expected to extend Trulance patent protection until 2032
Wednesday, 12 Apr 2017 08:00am EDT 

Synergy Pharmaceuticals Inc : Announces issuance of three new patents expected to extend Trulance (Plecanatide) patent protection until 2032 .United States Patent and Trademark Office (USPTO) has issued three new patents covering Trulance (Plecanatide).  Full Article

Synergy Pharmaceuticals reports qtrly net loss per common share $0.31
Wednesday, 1 Mar 2017 04:42pm EST 

Synergy Pharmaceuticals Inc : Synergy Pharmaceuticals reports fourth quarter and full year 2016 financial results and business update . Qtrly net loss per common share $0.31 . Q4 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S .Synergy pharmaceuticals inc- remain on-track to file a supplemental new drug application this month for trulance.  Full Article

Synergy Pharmaceuticals announces proposed public offering of common stock
Tuesday, 31 Jan 2017 04:01pm EST 

Synergy Pharmaceuticals Inc : Synergy Pharmaceuticals announces proposed public offering of common stock . Synergy Pharmaceuticals Inc- intends to use net proceeds from offering to fund its commercialization activities related to trulance . Synergy Pharmaceuticals Inc says to sell $125 million of its common stock .Synergy Pharmaceuticals Inc- also intends to use net proceeds from offering to further clinical development of plecanatide.  Full Article

Synergy Pharma's Trulance receives FDA approval for treatment of adults with chronic idiopathic constipation
Thursday, 19 Jan 2017 06:35pm EST 

Synergy Pharmaceuticals Inc : Synergy Pharmaceuticals' Trulance(TM) (Plecanatide) receives U.S. FDA approval for the treatment of adults with chronic idiopathic constipation .Synergy Pharmaceuticals - Plans to file new drug application supplement with clinical data later this quarter for Trulance.  Full Article

FDA approves Trulance for chronic idiopathic constipation
Thursday, 19 Jan 2017 04:05pm EST 

Synergy Pharmaceuticals Inc : FDA approves Trulance for chronic idiopathic constipation .FDA- Trulance is manufactured by New York, New York-based Synergy Pharmaceuticals Inc.  Full Article

Synergy Pharmaceuticals says positive results in second phase 3 trial of plecanatide in patients with irritable bowel syndrome with constipation
Thursday, 22 Dec 2016 04:30pm EST 

Synergy Pharmaceuticals Inc : Synergy Pharmaceuticals announces positive results in second phase 3 trial of plecanatide in patients with irritable bowel syndrome with constipation (ibs-c) . Synergy Pharmaceuticals Inc - plecanatide is under review by food and drug administration (fda) for treatment of chronic idiopathic constipation . Synergy Pharmaceuticals - most common adverse event was diarrhea which occurred in 5.4 pct of patients in 3 mg and 4.3% of patients in 6 mg dose groups . Synergy Pharmaceuticals Inc - overall responder endpoint is current regulatory endpoint required for U.S. approval in ibs-c . Preliminary analysis of data indicates that both plecanatide 3 mg and 6 mg doses met study's primary endpoint . Synergy Pharmaceuticals- pending approval in cic indication,plans to file new drug application supplement with clinical data for plecanatide in ibs-c in q1 2017 . Synergy Pharmaceuticals Inc - prescription drug user fee act (pdufa) target action date for plecanatide is January 29, 2017 . Synergy Pharmaceuticals says it plans to present further clinical data from both trials at an appropriate scientific meeting next year .Synergy Pharmaceuticals announces positive results in second phase 3 trial of plecanatide in patients with irritable bowel syndrome with constipation (ibs-c).  Full Article

Synergy Pharma enters privately-negotiated exchange agreements
Monday, 21 Nov 2016 05:19pm EST 

Synergy Pharmaceuticals Inc : Synergy Pharma-co entered privately-negotiated exchange agreements with certain holders of co's 7.50% convertible senior notes due 2019 . Synergy Pharmaceuticals-holders agreed to exchange aggregate amount of about $20.7 million of notes, accrued but unpaid interest under notes held by them .Synergy Pharmaceuticals-holders agreed to exchange total principal amount of $20.7 million in exchange for 7.6 million shares of co's common stock-sec filing.  Full Article

Synergy Pharma Q2 net loss $38.6 million
Monday, 8 Aug 2016 05:00pm EDT 

Synergy Pharmaceuticals Inc : Synergy pharmaceuticals reports second quarter 2016 financial results and business update .Net loss in q2 of 2016 was $38.6 million, as compared to a net loss of $33.7 million incurred in q2 of 2015.  Full Article

More From Around the Web

BRIEF-Synergy Pharmaceuticals reports Q1 sales $100,000

* Synergy Pharmaceuticals reports first quarter 2017 financial results and business update